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Background Non-replicating respiratory syncytial virus (RSV)
vaccine candidates could potentially prime for enhanced
respiratory disease (ERD) due to a T-cell-mediated
immunopathology, following RSV infection. Vaccines with built-in
immune response modifiers, such as Toll-like receptor (TLR)
ligands, may avoid such aberrant imprinting of the immune system.
Methods We developed reconstituted RSV envelopes (virosomes)
with incorporated TLR4 ligand, monophosphoryl lipid A (RSV-
MPLA virosomes). Immune responses and lung pathology after
vaccination and challenge were investigated in ERD-prone cotton
rats and compared with responses induced by live virus and
formaldehyde-inactivated vaccine (FI-RSV), a known cause of ERD
upon RSV challenge.
Results Vaccination with RSV-MPLA virosomes induced higher
levels of virus-neutralizing antibodies than FI-RSV or live virus
infection and provided protection against infection. FI-RSV, but not
RSV-MPLA virosomes, primed for increases in expression of Th2
cytokines IL-4, IL-5, IL-13, and Th1 cytokine IL-1b, 6 hour–5 days
after infection. By contrast, RSV-MPLA virosomes induced IFN-c
transcripts to similar levels as induced by live virus. Animals
vaccinated with FI-RSV, but not RSV-MPLA virosomes showed
alveolitis, with prominent neutrophil influx and peribronchiolar and
perivascular infiltrates.
Conclusion These results show that RSV-MPLA virosomes
represent a safe and immunogenic vaccine candidate that warrants
evaluation in a clinical setting.
Keywords Adjuvant, cotton rat, enhanced respiratory disease,
monophosphoryl lipid A, respiratory syncytial virus, vaccine,
virosomes.
Please cite this paper as: Kamphuis et al. (2013) A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection
against viral challenge without priming for enhanced disease in cotton rats. Influenza and Other Respiratory Viruses 7(6), 1227–1236.
Introduction
Respiratory syncytial virus (RSV) has been recognized as an
important vaccine target for over 60 years; however, there is
no vaccine on the market today. A clinical trial conducted in
the 1960s evaluated a formalin-inactivated, alum-absorbed
RSV preparation (FI-RSV) as a possible vaccine candidate.1
Infants vaccinated with FI-RSV who subsequently acquired a
natural infection, developed enhanced respiratory disease
(ERD), especially in the youngest group of vaccinees who
were na€ıve to RSV prior to vaccination, which led to the
death of two of these children.2,3 In those two infants, severe
bronchiolitis and alveolitis were observed with an influx of
neutrophils and mononuclear cells into the lungs.2 Although
the vaccine significantly increased RSV-specific antibody
titers in 95–100% of vaccinees, the induced antibodies failed
to neutralize the virus in half of the patients.4,5 Studies in
mice demonstrated that impaired Toll-Like receptor (TLR)
signaling by the vaccine results in low antibody affinity
maturation and, consequently, in the formation of poorly
virus-neutralizing antibodies.6 Furthermore, it has been
shown that FI-RSV induces a predominantly Th2-skewed
immune response.7,8 Therefore, the objective in the devel-
opment of non-replicating RSV vaccines is to generate a
formulation that induces high titers of neutralizing antibod-
ies without priming for T-cell responses that induce lung
pathology upon natural infection.
One way to induce protective immunity without priming
for immunopathology involves the addition of a Th1-
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lipopolysaccharide (LPS) derivative monophosphoryl lipid A
(MPLA) has been shown to skew the immune response to a
Th1-phenotype through the activation of TLR4.9 Addition-
ally, MPLA has an acceptable safety profile when co-
administered with vaccine antigens in multiple clinical trials
and is the only TLR ligand currently being used as an
adjuvant in licensed human vaccines.10–12 Furthermore, it
has been shown that addition of MPLA to FI-RSV alleviates
the symptoms of RSV-enhanced disease.13
In a recent study in mice, we showed that reconstituted
RSV viral envelopes (virosomes) containing viral membrane
proteins and incorporated MPLA but lacking the nucleo-
capsid represent a promising vaccine candidate.14 Immuni-
zation with these RSV-MPLA virosomes led to induction of
high levels of neutralizing antibodies and a balanced Th1/Th2
phenotype compared with FI-RSV immunization. Mice
immunized with RSV-MPLA virosomes cleared the virus
after infection and showed no signs of immunopathology.
Even though mice are a valuable model to assess vaccine-
induced immune responses, they are not permissive for RSV
replication and display a different form of ERD compared
with humans. Infiltration of eosinophils is a hallmark of FI-
RSV-induced ERD in mice, while in the clinical trial
conducted in the 1960s, analyses of autopsy samples
indicated excessive infiltrating neutrophils and only scarce
influx of eosinophils.8,15 Cotton rats (Sigmodon hispidus),
although still being semi-permissive, are more permissive for
RSV than mice, and this animal model also displays FI-RSV-
induced lung immunopathology with neutrophil
infiltration.15,16
The cotton rat was used for pre-clinical evaluation of the
prophylactic antibody palivizumab and has become the
small-animal model of choice for RSV vaccine develop-
ment.17 Recently, key cotton rat cytokine genes were
sequenced enabling the analysis of Th1/Th2 cytokine profiles
using qPCR.18 It was shown that immunization of cotton rats
with FI-RSV not only induces increased Th2 cytokine
expression, but also stimulates expression of several Th1-
associated cytokines after live virus challenge.13 The combi-
nation of the permissiveness of the cotton rat for RSV, the
occurrence of ERD and the new opportunity to profile Th1/
Th2 cytokine responses make this animal model very suitable
to study the safety and efficacy of RSV-MPLA virosomes.
Here, we show that RSV-MPLA virosomes induce a
superior immune response compared with FI-RSV or non-
adjuvanted RSV virosomes. It induces increased virus-
neutralizing antibody levels compared with levels induced
by FI-RSV or non-adjuvanted RSV virosomes, a strongly
reduced Th2 response compared with responses induced by
FI-RSV without inducing alveolitis with influx of neutrophils
in the lungs after challenge. These results, combined with the
responses to immunization we observed in mice, show that
RSV-MPLA virosomes represent a safe and immunogenic




Animal experiments were approved by the Committee for
Animal Experimentation (DEC) of the University Medical
Center Groningen, according to the Dutch Animal Protec-
tion Act (permit number DEC 5239D). Immunizations and
challenges were conducted under isoflurane anesthesia, and
every effort was made to minimize suffering of the animals.
Cells and virus
Respiratory syncytial virus strain A2 (ATCC VR1540) was
kindly donated by Mymetics BV (Leiden, the Netherlands).
The virus was grown in HEp-2 cells (ATCC, CL-23, Wesel,
Germany) in roller bottles in HEp-2 medium: DMEM
(Invitrogen, Breda, the Netherlands) supplemented with Pen/
Strep, L-glutamine, sodium bicarbonate, HEPES, sodium
pyruvate, 1X non-essential amino acids (all from Invitrogen)
and 2% FBS (Lonza-Biowhittaker, Basel, Switzerland) and
purified on sucrose gradients as described before.14
Vaccine formulations
Respiratory syncytial virus virosomes were generated as
described previously and contain the viral proteins F and G,
and to some extent M protein.19 Briefly, the RSV membrane
was dissolved in 100 mM 1,2 dihexanoyl-sn-glycero-3-phos-
phocholine (DCPC) in 5 mM Hepes, 145 mM NaCl, 1 mM
EDTA, pH 74 (HNE), and the nucleocapsid was removed
by ultracentrifugation. The supernatant was applied to a
dried film of a 2:1 mixture of egg phosphatidylcholine (PC)
and egg phosphatidylethanolamine (PE; Avanti Polar Lipids,
Alabaster, AL, USA) at a ratio of 850 nmol lipid per mg of
supernatant protein. For incorporation of MPLA, MPLA
from Salmonella minnesota Re 595 (Invivogen, Toulouse,
France) dissolved in 100 mM DCPC in HNE was added to
the protein lipid mixture at 1 mg MPLA per mg superna-
tant protein, incubated for 15 minute at 4°C, filtered
through a 01-lm filter, and dialyzed in a sterile Slide-A-
lyzer (10 kD cut-off; Thermo Scientific, Geel, Belgium)
against HNE buffer pH 74. After dialysis, virosomes were
kept at 4°C. A detailed procedure for production and
characterization of the RSV-MPLA virosomes has been
described before.14
FI-RSV was produced as reported before.15 FI-RSV was
diluted with HNE to contain 5 lg of RSV protein in a 50 ll
volume.
Animals and immunizations
Female outbred cotton rats (Hsd:Cotton Rat) of 4–6 weeks
old were obtained from Harlan (Indianapolis, IN, USA).
Kamphuis et al.
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Cotton sats received 50 ll RSV virosomes or RSV-MPLA
virosomes intramuscularly containing 5 lg of protein. Con-
trol cotton rats received 100 ll (106 TCID50) intranasally,
50 ll of HNE intramuscularly, or 50 ll (5 lg viral protein)
of FI-RSV intramuscularly. Vaccinations were given on day 0
and 21. On day 49, cotton rats were challenged with 106
TCID50 RSV intranasally. At the time of immunization and
challenge, blood was drawn by retro-orbital puncture. Six
hours or 5 days after challenge, cotton rats were sacrificed
and blood was drawn by heart puncture. Lungs were
removed aseptically, and one of the primary bronchi was
ligated just below the tracheal bifurcation with suture wire.
Approximately 20 mg of this lobe was removed and stored in
1 ml of RNA later (Qiagen, Venlo, the Netherlands) at
20°C for RNA isolation. The remainder of this lobe was
kept on ice in HEp2 medium containing 2% FBS, for virus
titration. The other half of the lung was fixed in 4%
formaldehyde in PBS under 20 cm of water pressure to
preserve the structure of the lungs for lung histopathology
analyses. Control cotton rats used for RNA expression
analyses were sacrificed as described above without prior
challenge.
IgG antibody ELISA
Respiratory syncytial virus-specific serum IgG titers were
determined using standard protocols19 using horseradish
peroxidase–coupled goat anti-mouse IgG (1030-05; Southern
Biotech, Birmingham, AL, USA) which was cross-reactive for
cotton rat IgG.
Virus titration and microneutralization assay
Virus titers were determined by TCID50 as described
previously.14 RSV virus neutralization titers were determined
by incubation of twofold serially diluted heat-inactivated
(30 minute, 56°C) cotton rat serum with 70 TCID50 of RSV
for 2 hour and subsequent titration of this mixture on HEp-
2 cells as described before.14 The neutralization titer was
calculated with the Reed & Muench method,20 as the dilution
that neutralizes infection in 50% of the wells.
Lung histopathology
The inflated lungs were embedded in paraffin and 4-lm
slices were cut. The slides were then stained with hematoxylin
and eosin (H&E) using standard procedures. Subsequently,
perivasculitis, peribronchiolitis, and alveolitis were assessed
by light microscopy. Lungs from three animals per group
were evaluated, and the histology was judged in a blinded
fashion by two different investigators. Neutrophils were
identified based on morphology. Numbers of neutrophils
were determined in four areas per slide and three animals per
group and counted by two different investigators. The
average of these counts was considered to represent an
objective quantification of neutrophil influx.
Lung RNA isolation
Lung samples stored in RNA later (Qiagen) were transferred
to tubes containing 300 ll RLT buffer (Qiagen) and
homogenized using disposable pestles with a pestle motor
(VWR, Amsterdam, the Netherlands). Subsequently RNA
was isolated with an RNeasy mini kit (Qiagen) according to
the manufacturer’s protocol. After isolation, RNA concen-
tration was determined on a Nanodrop (Thermo scientific,
Wilmington, DE, USA).
cDNA synthesis and qPCR
cDNA synthesis and qPCR were performed using the Verso
cDNA synthesis kit (Acros Organics, Geel, Belgium) and
Absolute QPCR SYBR Green Mix (Westburg, Leusden, the
Netherlands) according to the manufacturer’s protocols.
Cotton rat cytokine sequences were obtained from NCBI18
and used to generate primers that yield products of
approximately 125 bp (Table 1). PCR analyses were run on
an Applied Biosystems AB7500 Real-Time PCR system
(Applied Biosystems, Nieuwerkerk ad IJssel, the Netherlands)
Table 1. Primers for cotton rat cytokine RT-PCR
Sense primer Antisense primer Product length
Thl
IL-1b GTGCTGTCTGACCCATGTGAGC GCCACTGGTATCTTGGTGCTGC 122
IFN-c CATCAACACCATCAGGGCGGAC TGACAGCTTTGCGCTGGACC 125
IL-12-p40 CCACTCACGTCTGCTGCTTCAC ACCGGCCAGAGTAATTTGCTGC 125
Th2
IL-4 GCTTCCCAGGTGCTTCGCAAG TGGAGACAGACTGCTGATGCCC 120
IL-5 GGGGCACTGTGGAAACGCTATTC GCAGGTAATCCAGGAACTGCCG 117
IL-9 TGTGACCAGTTGCTTGTGTCTTCC ACCCGATTGAAAAGAACCGAGAACC 126
IL-13 TGCCTCGATGCATGTCTCCTCC GCTGTCAGGTCCACGCTCCATAC 124
Housekeeping gene
b-actin CCCCAAGGCCAACCGTGAAAAG CACAATGCCAGTGGTACGACCAG 124
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with the following conditions: 15 minute 95°C, 40 times
30 second 95°C, 30 second 60°C followed by a melt curve.
Relative transcript abundance was calculated using the 2ddCt
method comparing Ct (cycle threshold) values from the
immunized and challenged cotton rats to non-immunized,
non-challenged cotton rats corrected for Ct values for the
housekeeping gene b-actin.
Statistical analyses
All statistical analyses were performed with GRAPHPAD PRISM
5.00 for Mac OSX, (GraphPad Software, San Diego, CA,
USA, www.graphpad.com). Statistical significance was
assessed using a Mann–Whitney U-test. P-values of 005 or
lower were considered to represent significant differences.
Results
Immunogenicity of RSV-MPLA virosomes
Virosomes were produced and analyzed as described
before.19 To determine the immunogenicity of RSV viro-
somes and RSV-MPLA virosomes, serum samples from
immunized cotton rats, collected on day 21 and 49, were
analyzed for RSV-specific IgG antibodies (Figure 1A).
Immunization with RSV virosomes induced a significantly
higher RSV-specific IgG titer in serum than immunization
with FI-RSV or live virus. The inclusion of MPLA in the RSV
virosomes significantly increased the antibody titer to an
approximately twofold higher level.
To determine the virus-neutralizing capacity of the RSV-
specific serum antibodies, a microneutralization test was
performed (Figure 1B). Although FI-RSV induced similar
levels of RSV-specific antibodies compared with immuniza-
tion with live virus, the antibodies induced by FI-RSV had a
significantly lower capacity to neutralize the virus (Fig-
ure 1B). Sera from cotton rats immunized with RSV
virosomes did not show increased capacity to neutralize the
virus compared with sera from FI-RSV-immunized animals.
Sera from cotton rats immunized with RSV-MPLA viro-
somes demonstrated significantly higher levels of neutralizing
antibodies compared with sera from animals immunized
with FI-RSV or non-adjuvanted virosomes.
Protection against RSV infection
To determine whether immunization with MPLA-adjuvant-
ed RSV virosomes could also induce a protective immune
response in vivo, animals were immunized and challenged
with live RSV and lung virus titers were determined
(Figure 2). At 6 hour post-infection, RSV was recovered
A
B
Figure 1. Antibody responses to respiratory syncytial virus (RSV)
vaccination. Cotton rats were immunized twice (day 1, prime and 21,
boost) with virosomes, FI-RSV or live virus. (A) On day 21 and 49, blood
was drawn and RSV-specific IgG titers in serum were determined. (B) Virus
neutralization titer of serum on day 49 (Mann–Whitney U-test *P < 005,
**P < 001, ***P < 0001).
A
B
Figure 2. In vivo virus clearance after challenge. Cotton rats were
challenged with live RSV at day 49. (A) Five cotton rats per group were
sacrificed at 6 hours post-challenge and lung virus titers were determined
by TCID50. (B) Seven cotton rats per group were sacrificed at 5 days post-
challenge and lung virus titers were determined by TCID50. Values below
10 TCID50 were not detectable (Mann–Whitney U-test **P < 001,
***P < 0001). RSV, respiratory syncytial virus.
Kamphuis et al.
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from three of five control animals with titers of approxi-
mately 102 TCID50/gram lung. None of the immunized
animals had detectable virus in their lungs at this time point
(Figure 2A). At 5 days post-challenge, increased RSV viral
titers were detected in the lungs of all control animals, to
above 104 TCID50/gram lung, indicating virus replication in
these animals. In contrast, no RSV was detected in the lungs
of the animals immunized with RSV virosomes, RSV-MPLA
virosomes, FI-RSV, or live virus (Figure 2B).
Local immune responses upon RSV infection
To analyze whether RSV-MPLA virosomes prime for
immune responses associated with ERD, cotton rats were
vaccinated and challenged as described above and cytokine
gene expression levels in the lungs of the animals were
assessed by qPCR (Figures 3 and 4).
At 6 hour after infection, cotton rats immunized with FI-
RSV showed a significant increase in Th2-associated
cytokines IL-4, IL-5, IL-9, and IL-13 mRNA expression
(Figure 3). At this time point, cotton rats immunized with
RSV virosomes showed increased levels of IL-5 mRNA as
well. In contrast, animals immunized with RSV-MPLA
virosomes or live virus did not show significant increases
in the expression of Th2-associated cytokines at this early
time point. At 5 days post-infection, IL-4, IL-5, and IL-13
expression remained high in animals immunized with FI-
RSV. In contrast, animals immunized with RSV virosomes,
RSV-MPLA virosomes, or live virus only showed background
mRNA levels of these cytokines.
Animals immunized with FI-RSV also showed a significant
increase in the Th1-associated cytokine IL-1b, but not IL-12
or IFN-c mRNA (Figure 4). Animals immunized with live
virus showed early increases in expression levels of IL-1b, IL-
12, and IFN-c mRNA, while non-immunized animals had
increased expression levels of IL-1b and IL-12, but not IFN-c
mRNA at 6 hour post-infection. The levels of IL-12 and IFN-
c mRNA were significantly higher in animals immunized
with live virus than in animals immunized with RSV
virosomes, but similar to levels in animals immunized with
RSV-MPLA virosomes. At 5 days post-infection, all the
Figure 3. Th2-type cytokine expression in the lungs of vaccinated and challenged animals. Cotton rats were vaccinated and challenged as in Figure 2,
and at 6 hours (open bars) and 5 days (solid bars) post-infection, lung cytokine expression was determined by qPCR. Values are relative quantities (RQ)
compared with na€ıve cotton rats (horizontal line at RQ = 1; Mann–Whitney U-test *P < 05, **P < 001, ***P < 0001 comparing vaccine group to
vaccine group. #P < 05, ###P < 0001 comparing expression values of the vaccinated and challenged cotton rat to expression in na€ıve cotton rats).
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Th1-type cytokine expression levels in the immunized cotton
rats had returned to background levels, that is, levels similar
to non-immunized, non-infected animals. Non-immunized
animals, however, showed increased levels of IL-12 and IFN-
c at 5 days post-infection.
Immunopathology upon RSV infection
To assess whether RSV-MPLA virosomes primed for the
induction of lung pathology upon infection, we examined
the lungs of immunized and challenged animals by means of
histology. The lungs of non-immunized animals showed no
signs of alveolitis, and the peribronchial and perivascular
regions were also free of infiltrates (Figure 5A,B). In contrast,
the lungs of cotton rats immunized with FI-RSV showed
prominent alveolitis as well as peribronchial and perivascular
infiltrates (Figure 5C,D). The lungs of animals immunized
with RSV virosomes also showed some signs of alveolitis and
infiltrates in the peribronchial and perivascular regions
(Figure 5E,F). In contrast, cotton rats immunized with
RSV-MPLA virosomes showed no sign of alveolitis or
infiltrates (Figure 5G,H) and were comparable to non-
immunized animals or animals that received live virus
immunization (Figure 5I,J).
Finally, infiltrating neutrophils in the alveoli, a hallmark of
ERD in both cotton rat and humans,15 were enumerated. The
lungs of cotton rats immunized with RSV-MPLA virosomes
contained low numbers of infiltrates similar to those seen in
non-immunized animals or animals immunized with live
virus. Although we observed an increased number of
infiltrating neutrophils in the lungs of the cotton rats
immunized with RSV virosomes, the numbers were signif-
icantly lower than the numbers induced by immunization
with FI-RSV (Figure 6).
Discussion
The induction of ERD by FI-RSV in the clinical trial
conducted in the 1960s followed by observations that also
other, non-adjuvanted, inactivated vaccine formulations can
prime for Th2-type responses and ERD upon RSV infection
has tempered enthusiasm for further development of these
types of vaccines.21 Recent insights in the importance of TLR
signaling in immunomodulation suggest that addition of
TLR ligands to vaccines represents a powerful approach to
steer immune responses toward the desired phenotype and
have revived the development of inactivated RSV vaccines.
Figure 4. Th1-type cytokine expression in the lungs of vaccinated and challenged animals. As Figure 3 but for Th1-type cytokines. Open bars represent
relative transcription abundance at 6 hours post-challenge and solid bars at 5 days post-challenge.
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Here, we show that a non-replicating virosomal RSV vaccine,
with incorporated MPLA, induces virus-neutralizing
immune responses without priming for excess Th2-type
responses or ERD in RSV-permissive and ERD-prone cotton
rats.
In cotton rats immunized with FI-RSV and subsequently
challenged with live virus, we observed a strongly upregu-
lated expression of Th2 cytokines including IL-4, IL-5, IL-9,
and IL-13. Studies in mice have shown that expression of
these cytokines in lungs is implicated in allergen-induced
asthma, rhinitis, and anaphylaxis.22–25 IL-5, for example,
directly activates eosinophils and is therefore an important
factor in allergic reactions. IL-9 induces IL-13 expression in
the lungs, affecting airway epithelium and contributing to
signs of lung pathology.26 Furthermore, IL-4 and IL-13
upregulate vascular cell adhesion molecule-1 (VCAM-1),
which induces migration of eosinophils and lymphocytes.
Additionally, upregulation of IL-13 induces mucus secretion
in the lungs.27 Therefore, it is likely that the expression of
Th2 cytokines in the lungs of cotton rats, immunized with
FI-RSV and subsequently challenged with live virus, may
have contributed to the observed alveolar, perivascular, and
peribronchial infiltrations.
The exact mechanism by which FI-RSV skews the immune
response to a Th2 phenotype is unknown and most likely






Figure 5. Cotton rat lung pathology. Cotton rats
were vaccinated and challenged as in Figure 2. At
5 days post–challenge, lungs were removed, fixed
in formalin under 20 cm water pressure to preserve
the structure of the lungs, embedded in paraffin
and stained with H&E. (A, B) No vaccine. (C, D) FI-
RSV. (E, F) RSV virosomes. (G, H) RSV-MPLA
virosomes. (I, J) Live virus. Green arrows,
perivascular infiltrates. Green arrowheads,
peribronchial infiltrates. Red arrows, alveolar
infiltrates.
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and the presence of cell culture proteins29 and alum30,31 have
all been shown to contribute to Th2-associated cytokine
expression and ERD. RSV virosomes, on the other hand, are
generated from untreated, purified virus, do not contain
alum as an adjuvant, and therefore do not induce excessive
Th2 cytokine expression.
Respiratory syncytial virus-monophosphoryl lipid A viro-
somes stimulated the expression of the Th1-associated
cytokine IFN-c, but not of Il-1b or IL-12. In contrast,
priming with live virus resulted in expression of all of these
three Th1 cytokines after infection, reflecting a more Th1-
skewed response than the response induced by RSV-MPLA
virosomes. In a previous study in Th2-prone BALB/c mice,
we also observed induction of a balanced Th1/Th2 response
by RSV-MPLA virosomes.14 In the latter study, upon
immunization of the animals with RSV-MPLA virosomes,
we observed higher levels of virus-neutralizing, Th1-signa-
ture, IgG2a antibodies and IFN-c expression, compared with
the corresponding responses in mice immunized with
FI-RSV. However, similar to the observations made in the
present study, the Th1-skewing effect was more pronounced
after priming with live virus than after immunization with
RSV-MPLA virosomes. This is in agreement with the
findings of Boukhvalova et al.,13 who added MPLA to
FI-RSV and, after immunization and subsequent challenge
in cotton rats, did not observe a strong Th1-skewed response
either. They did, however, note a dampening of the
pronounced Th2-type response induced by FI-RSV alone.
Comparison of the results obtained using RSV virosomes
versus RSV-MPLA virosomes demonstrates that MPLA is
essential for complete prevention of ERD. Even though the
expression of Th2 cytokines in cotton rats immunized with
non-adjuvanted RSV virosomes was much lower than that in
FI-RSV-immunized animals, these animals did display signs
of lung pathology. It is possible that these neutrophils were
attracted through complement activation, which may have
occurred as a result of induction of antibodies with low
affinity and low neutralizing capacity (Figure 1), leading to
the deposition of immune complexes in the lungs. This may
lead to complement fixation, activation, and chemo-attrac-
tion of neutrophils by complement factor fragments such as
C3a, C4a, and C5a.32,33 C3a may additionally induce
bronchoconstriction, another symptom of ERD.2,34 Impor-
tantly, immune complex deposition has been demonstrated
to play an important role in ERD in mice, and immune
complex-dependent C4d deposition has been found in lung
biopsies from the children who died of ERD in the trial
conducted in the 1960s.35 Unfortunately, there are, to our
knowledge, currently no reagents available to directly inves-
tigate immune complex formation and complement fixation
in cotton rats.
As indicated before, FI-RSV induces low-affinity antibodies
that have poor virus-neutralizing capacity.4,6 Accordingly,
our data indicate that not only FI-RSV, but also non-
adjuvanted RSV virosomes, induced antibodies with a lower
in vitro capacity for neutralization of RSV, compared with
antibodies induced by RSV-MPLA virosomes or live virus.
Possibly, this points to a lower antibody affinity maturation
induced by FI-RSV or non-adjuvanted RSV virosomes. In this
respect, TLR4 activation by MPLA in RSV-MPLA virosomes
or, for that matter, TLR3 activation by RNA in replicative
virus are likely to induce proper antibody affinity maturation
yielding antibodies more capable of virus neutralization. In
the context of inactivated RSV vaccines, it therefore appears
that proper TLR activation is essential and sufficient to ensure
the prevention of ERD upon viral challenge.
Apart from stimulating the induction of high levels of
high-affinity antibodies, TLR signaling also improves per-
sistence of the antibody response.36 Previous reports15 and
our data (Figure 2) show that also immunization with FI-
RSV gives rise to an antibody response capable of virus
neutralization in vivo. This is most likely due to the high
abundance of these antibodies. Primary immunization with
FI-RSV and non-adjuvanted RSV virosomes already induced
significant levels of antibodies that were slightly, but
significantly, increased by a booster immunization (Fig-
ure 1). With respect to the latter, it is possible that
administration of the booster immunization at a later time
point would have given a more pronounced booster
response. However, the lack of TLR signaling upon immu-
nization with FI-RSV for example may cause these antibod-
ies to wane rapidly after the second immunization. In
comparison with FI-RSV, RSV-MPLA virosomes, through
their ability to activate TLRs, may induce a more sustained
high level of antibodies, but this remains to be further
investigated.
Taken together, our results show that RSV-MPLA viro-
somes induce high levels of virus-neutralizing antibodies,
which are able to confer protection from RSV infection in
cotton rats. Immunization with RSV-MPLA virosomes does
not lead to increased expression of Th2-associated cytokines
Figure 6. Alveolar infiltration with neutrophils. Lungs were treated as in
Figure 5, and the numbers of neutrophils per mm2 were determined by
light microscopy in four areas per slide and three animals per group.
(Mann–Whitney U-test *P < 05, **P < 001, ***P < 0001). MPLA,
monophosphoryl lipid A; RSV, respiratory syncytial virus.
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implicated in the induction of ERD. These data demonstrate
the efficacy and safety of RSV-MPLA virosomes as a possible
RSV vaccine candidate and warrant further evaluation in
clinical trials.
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